Accelerate Diagnostics (AXDX) versus Horiba (HRIBF) Critical Comparison

Horiba (OTCMKTS: HRIBF) and Accelerate Diagnostics (NASDAQ:AXDX) are both industrial products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Profitability

This table compares Horiba and Accelerate Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Horiba N/A N/A N/A
Accelerate Diagnostics -1,520.99% -54.66% -51.90%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Horiba and Accelerate Diagnostics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Horiba 0 0 0 0 N/A
Accelerate Diagnostics 0 1 1 0 2.50

Accelerate Diagnostics has a consensus price target of $33.00, indicating a potential upside of 42.24%. Given Accelerate Diagnostics’ higher probable upside, analysts plainly believe Accelerate Diagnostics is more favorable than Horiba.

Valuation & Earnings

This table compares Horiba and Accelerate Diagnostics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Horiba $1.57 billion 1.66 $130.57 million $3.07 19.88
Accelerate Diagnostics $4.18 million 309.65 -$64.02 million ($1.16) -20.00

Horiba has higher revenue and earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Horiba, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Horiba has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500. Comparatively, Accelerate Diagnostics has a beta of 2.13, suggesting that its share price is 113% more volatile than the S&P 500.

Institutional & Insider Ownership

44.9% of Accelerate Diagnostics shares are held by institutional investors. 50.0% of Accelerate Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Horiba beats Accelerate Diagnostics on 7 of the 13 factors compared between the two stocks.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.

Receive News & Ratings for Horiba Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horiba and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Markel Co.  Vice Chairman Steven A. Markel Sells 200 Shares
Markel Co. Vice Chairman Steven A. Markel Sells 200 Shares
Bottomline Technologies, Inc.  Director Peter Gibson Purchases 4,000 Shares
Bottomline Technologies, Inc. Director Peter Gibson Purchases 4,000 Shares
Old Dominion Freight Line  Director Leo H. Suggs Sells 800 Shares of Stock
Old Dominion Freight Line Director Leo H. Suggs Sells 800 Shares of Stock
Cara Therapeutics  SVP Frederique Ph.D. Menzaghi Sells 9,000 Shares
Cara Therapeutics SVP Frederique Ph.D. Menzaghi Sells 9,000 Shares
Analysts Set Nexeo Solutions  Price Target at $11.17
Analysts Set Nexeo Solutions Price Target at $11.17
Hologic, Inc.  Given Average Recommendation of “Hold” by Analysts
Hologic, Inc. Given Average Recommendation of “Hold” by Analysts


© 2006-2018 Ticker Report. Google+.